Corinne Vandermeulen
Waver, VLG, Belgium
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 47 publications
The role of immunosenescence and chronic medical conditions on the immune response to respiratory syncytial virus in older individuals.
Journal: Expert review of clinical immunology
Published: July 03, 2026
Immune persistence and safety of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein-based vaccine in adults 50-59 years of age, including at-increased-risk adults: A randomized controlled trial.
Journal: Human vaccines & immunotherapeutics
Published: November 06, 2025
Host immune response to respiratory syncytial virus infection and its contribution to protection and susceptibility in adults: a systematic literature review.
Journal: Expert review of clinical immunology
Published: April 25, 2025
Dosimetry and kinetic modelling of [18F]JNJ-64511070, a novel PET ligand to quantify AMPA-associated TARP-γ8 receptors in the human brain.
Journal: European journal of nuclear medicine and molecular imaging
Published: March 19, 2025
Immunogenicity of the 9-valent human papillomavirus vaccine: Post hoc analysis from five phase 3 studies.
Journal: Human vaccines & immunotherapeutics
Published: January 22, 2025
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age.
Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
Published: February 29, 2024
Safety and Immunogenicity of a Revaccination With a Respiratory Syncytial Virus Prefusion F Vaccine in Older Adults: A Phase 2b Study.
Journal: The Journal of infectious diseases
Published: April 19, 2023
Respiratory Syncytial Virus Disease Burden in Community-Dwelling and Long-Term Care Facility Older Adults in Europe and the United States: A Prospective Study.
Journal: Open forum infectious diseases
Published: October 27, 2022
Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1/2 Randomized Clinical Trial.
Journal: The Journal of infectious diseases
Published: May 27, 2022
The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value.
Journal: Acta clinica Belgica
Published: February 16, 2022
Doubt at the core: Unspoken vaccine hesitancy among healthcare workers.
Journal: The Lancet regional health. Europe
Published: December 20, 2021
Using provocative design to foster electronic informed consent innovation.
Journal: BMC medical informatics and decision making
Published: December 17, 2021
Last Updated: 09/26/2026